Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A (2015) A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
The possibility that GLP-1 medicines could reduce craving or alter reward-related behaviour has become an active area of investigation, particularly as these drugs become more widely used for diabetes, obesity and weight management
It's a life-saving medicine
Bianchi, Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis
Your health information will be shared with the clinical providers and pharmacies involved in your care
Weight loss timelines can vary, but many patients begin to notice changes within the first few weeks of starting GLP-1 medications